A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis
Background: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. Aims: The current study assessed the effectiveness of itolizumab in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Indian Dermatology Online Journal |
| Subjects: | |
| Online Access: | http://www.idoj.in/article.asp?issn=2229-5178;year=2017;volume=8;issue=4;spage=246;epage=249;aulast=Parthasaradhi |
| _version_ | 1818544161139195904 |
|---|---|
| author | Anchala Parthasaradhi Vinay Singh S G Parasramani Nishi Yadav D S Krupashankar Manish Soni Rakesh Bansal |
| author_facet | Anchala Parthasaradhi Vinay Singh S G Parasramani Nishi Yadav D S Krupashankar Manish Soni Rakesh Bansal |
| author_sort | Anchala Parthasaradhi |
| collection | DOAJ |
| description | Background: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. Aims: The current study assessed the effectiveness of itolizumab in real-world settings. Materials and Methods: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore. Registry data of 155 patients who were prescribed itolizumab at a dose of 1.6 mg/kg every 2 weeks for the first 12 weeks followed by 1.6 mg/kg every 4 weeks for up to 24 weeks for chronic plaque psoriasis. Results: In the study, 35.48% completed itolizumab for 12 weeks and 76.59% of these patients achieved PASI 75. Furthermore, 24.51% patients completed the full Itolizumab regimen for 24 weeks, of whom 92.01% patients achieved PASI 75. The mean percent change in DLQI scores at weeks 12 and 24 were 60.19 and 82.72, respectively. Adverse events and infusion reactions noted in the study were generally of mild to moderate severity. Conclusion: Itolizumab is a safe and effective option in treatment-compliant patients with chronic plaque psoriasis. Effects of putative compliance-modulators such as cost, route of administration, and delayed onset of action warrant further investigation. |
| first_indexed | 2024-12-11T22:44:50Z |
| format | Article |
| id | doaj.art-ac17f9b14b154fc99622c556c7dda902 |
| institution | Directory Open Access Journal |
| issn | 2229-5178 |
| language | English |
| last_indexed | 2024-12-11T22:44:50Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Dermatology Online Journal |
| spelling | doaj.art-ac17f9b14b154fc99622c556c7dda9022022-12-22T00:47:39ZengWolters Kluwer Medknow PublicationsIndian Dermatology Online Journal2229-51782017-01-018424624910.4103/idoj.IDOJ_330_16A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasisAnchala ParthasaradhiVinay SinghS G ParasramaniNishi YadavD S KrupashankarManish SoniRakesh BansalBackground: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. Aims: The current study assessed the effectiveness of itolizumab in real-world settings. Materials and Methods: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore. Registry data of 155 patients who were prescribed itolizumab at a dose of 1.6 mg/kg every 2 weeks for the first 12 weeks followed by 1.6 mg/kg every 4 weeks for up to 24 weeks for chronic plaque psoriasis. Results: In the study, 35.48% completed itolizumab for 12 weeks and 76.59% of these patients achieved PASI 75. Furthermore, 24.51% patients completed the full Itolizumab regimen for 24 weeks, of whom 92.01% patients achieved PASI 75. The mean percent change in DLQI scores at weeks 12 and 24 were 60.19 and 82.72, respectively. Adverse events and infusion reactions noted in the study were generally of mild to moderate severity. Conclusion: Itolizumab is a safe and effective option in treatment-compliant patients with chronic plaque psoriasis. Effects of putative compliance-modulators such as cost, route of administration, and delayed onset of action warrant further investigation.http://www.idoj.in/article.asp?issn=2229-5178;year=2017;volume=8;issue=4;spage=246;epage=249;aulast=ParthasaradhiComplianceitolizumabplaque psoriasis |
| spellingShingle | Anchala Parthasaradhi Vinay Singh S G Parasramani Nishi Yadav D S Krupashankar Manish Soni Rakesh Bansal A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis Indian Dermatology Online Journal Compliance itolizumab plaque psoriasis |
| title | A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| title_full | A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| title_fullStr | A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| title_full_unstemmed | A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| title_short | A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| title_sort | real world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis |
| topic | Compliance itolizumab plaque psoriasis |
| url | http://www.idoj.in/article.asp?issn=2229-5178;year=2017;volume=8;issue=4;spage=246;epage=249;aulast=Parthasaradhi |
| work_keys_str_mv | AT anchalaparthasaradhi arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT vinaysingh arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT sgparasramani arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT nishiyadav arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT dskrupashankar arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT manishsoni arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT rakeshbansal arealworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT anchalaparthasaradhi realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT vinaysingh realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT sgparasramani realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT nishiyadav realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT dskrupashankar realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT manishsoni realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis AT rakeshbansal realworldstudytoassesstheeffectivenessofitolizumabinpatientswithchronicplaquepsoriasis |